Our Story

Meet the highly merited team of internationally recognised experts within the vaccine industry

Read More

Read more

The Portfolio

Learn how we transform existing and novel vaccines into effective treatments of tomorrow

Read More

Read more

News

Eurocine Vaccines confirms good immunological effect in preclinical study with the chlamydia vaccine candidate

Eurocine Vaccines AB (“Eurocine Vaccines”) confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate. The study confirms that an adapted variant of the vaccine, designed to meet the regulatory requirements for a finished product, is highly immunogenic. The good immunological effect of the tested vaccine surpasses, by a good margin, what in previous studies with our vaccine has provided protection in preclinical models.

Read More

Eurocine Vaccines bekräftar god immunologisk effekt i preklinisk studie med klamydiavaccinkandidaten

Eurocine Vaccines AB (”Eurocine Vaccines”) bekräftar god immunologisk effekt i en preklinisk djurstudie med sin klamydiavaccinkandidat. Studien konfirmerar att en anpassad variant av vaccinet, utformad för att möta de regulatoriska kraven på en färdig produkt, är mycket immunogen. Den goda immunologiska effekten av det testade vaccinet överträffar med god marginal det som i tidigare studier med vårt vaccin gett skydd i prekliniska modeller.

Read More

Eurocine Vaccines publishes half-year report for July-December 2020

Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes an interim report for the first half year of 2020. Below is a summary of the report. The full report is available on the Euroccine Vaccines website (https://www.eurocine-vaccines.com/) and as an attachment.

Read More

Do you want to follow Eurocine Vaccines development?

Share our ambition developing more effective vaccines. Fill in your e-mail address and we will update you with the latest Press Releases and Stories.

Start your subscription here »